Vaccinia virus-induced cell motility requires F11L-mediated inhibition of RhoA signaling

Science

Volumn 311, Issue 5759, 2006, Pages 377-381

  Valderrama, Ferran ^a   Cordeiro, João V ^a   Schleich, Sibylle ^a   Frischknecht, Friedrich ^a,b   Way, Michael ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITION; GENES; MORPHOLOGY; RNA; SIGNALING; VIRUSES;

CELL MOTILITY; MORPHOGENESIS; RHO-ASSOCIATED KINASE; RHOA SIGNALING;

CELLS;

BINDING PROTEIN; PROTEIN F11L; PROTEIN MDIA; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

BIOLOGY;

ARTICLE; BINDING SITE; CELL MIGRATION; CELL MOTILITY; HUMAN; HUMAN CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS MORPHOGENESIS;

AMIDES; ANIMALS; CELL LINE; CELL MOVEMENT; CYTOSKELETAL PROTEINS; ENZYME INHIBITORS; GENES, VIRAL; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MORPHOGENESIS; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RECOMBINANT FUSION PROTEINS; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS ASSEMBLY;

VACCINIA VIRUS;

EID: 31144458118     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1122411     Document Type: Article

References (20)

1. A. J. Ridley et al., Science 302, 1704 (2003).
2. P. Martin, S. M. Parkhurst, Development 131, 3021 (2004).
3. P. Friedl, K. Wolf, Nat. Rev. Cancer 3, 362 (2003).
4. N. O. Carragher, M. C. Frame, Trends Cell Biol. 14, 241 (2004).
5. C. M. Sanderson, G. L. Smith, J. Virol. 72, 9924 (1998).
6. C. M. Sanderson, M. Way, G. L. Smith, J. Virol. 72, 1235 (1998).
7. M. W. Carroll, B. Moss, Virology 238, 198 (1997).
8. I. Drexler, K. Heller, B. Wahren, V. Erfle, G. Sutter, J. Gen. Virol. 79, 347 (1998).
9. L. S. Wyatt et al., Virology 251, 334 (1998).
10. See supporting data on Science Online.
11. R. Dvorsky, L. Blumenstein, I. R. Vetter, M. R. Ahmadian, J. Biol. Chem. 279, 7098 (2004).
12. E. Sahai, A. S. Alberts, R. Treisman, EMBO J. 17, 1350 (1998).
13. R. A. Worthylake, S. Lemoine, J. M. Watson, K. Burridge, J. Cell Biol. 154, 147 (2001).
14. R. A. Worthylake, K. Burridge, J. Biol. Chem. 278, 13578 (2003).
15. A. Smith, M. Bracke, B. Leitinger, J. C. Porter, N. Hogg, J. Cell Sci. 116, 3123 (2003).
16. K. Riento, A. J. Ridley, Not. Rev. Mol. Cell Biol. 4, 446 (2003).
17. S. E. Kato, F. A. Greco, C. R. Damaso, R. C. Condit, N. Moussatche, J. Virol. Methods 115, 31 (2004).
18. M. C. Sancho, S. Schleich, G. Griffiths, J. Krijnse-Locker, J. Virol. 76, 8318 (2002).
19. J. C. Gallego-Gomez et al., J. Virol. 77, 10606 (2003).
20. We thank J. Krijnse-Locker (European Molecular Biology Laboratory, Heidelberg, Germany) and A. Alberts (Van Andel Research Institute, Grand Rapids, MI) for providing antibodies. We also thank B. Moss (National Institute of Allergy and Infectious Diseases, Bethesda, MD) for providing MVA recombinants, E. Sahai (Cancer Research UK, London) for the RhoV14E40L clone, and P. Traktman (Department of Microbiology and Molecular Genetics, WI) for discussions about siRNA in infected cells. We thank the Way lab, E. Sahai, N. Hogg, and R. Treisman (Cancer Research UK, London) for helpful comments on the manuscript. F.V. was supported by a European Community Marie Curie Fellowship (Number HPMF-CT-2000-01021).